INTRODUCTION {#jcla21549-sec-0050}
============

Diabetic nephropathy is a major cause of death worldwide in patients with diabetes mellitus (DM). Microalbuminuria has been recognized as an early predictor of nephropathy and has, therefore, become an important target for screening [1](#jcla21549-bib-0001){ref-type="ref"}. The urinary albumin excretion rate has been selected as a urinary marker because of its significance in the pathophysiology of diabetic nephropathy and its potential associations with the other markers being studied [2](#jcla21549-bib-0002){ref-type="ref"}, [3](#jcla21549-bib-0003){ref-type="ref"}. Furthermore, urinary *N*‐acetyl‐β‐[d]{.smallcaps}‐glucosaminidase (NAG) has also been identified as a possible marker for diabetic nephropathy [4](#jcla21549-bib-0004){ref-type="ref"}, [5](#jcla21549-bib-0005){ref-type="ref"}. The Diabetes Control and Complications Trial has recently shown that early urinary elevations of albumin and NAG in type 1 DM independently predict future microalbuminuria and macroalbuminuria [3](#jcla21549-bib-0003){ref-type="ref"}.

NAG is a widely distributed lysosomal enzyme that has a molecular weight of 140 kDa and is present at highest concentrations in the renal proximal tubules [6](#jcla21549-bib-0006){ref-type="ref"}. Because urinary levels of NAG are increased in glomerulonephritis, tubulointerstitial diseases, renal allograft rejection, and toxic renal injury [7](#jcla21549-bib-0007){ref-type="ref"}, [8](#jcla21549-bib-0008){ref-type="ref"}, [9](#jcla21549-bib-0009){ref-type="ref"}, [10](#jcla21549-bib-0010){ref-type="ref"}, they have been used to evaluate and predict subtle degrees of renal injury. Increased urinary levels of NAG have been reported in both type 1 and 2 DM [4](#jcla21549-bib-0004){ref-type="ref"}, [11](#jcla21549-bib-0011){ref-type="ref"}, [12](#jcla21549-bib-0012){ref-type="ref"}. Moreover, a new marker for glycemia developed in Japan, 1,5‐anhydroglucitol (1,5‐AG), is a specific index of postprandial hyperglycemia. A relationship between serum 1,5‐AG and urinary NAG in type 2 DM has been reported [13](#jcla21549-bib-0013){ref-type="ref"}. However, to date, only a few studies have examined urinary NAG levels in subjects with impaired glucose tolerance (IGT) [14](#jcla21549-bib-0014){ref-type="ref"}, [15](#jcla21549-bib-0015){ref-type="ref"}. Furthermore, the relationships among urinary NAG, plasma glucose levels, and other markers have not been examined at preloading or during the oral glucose tolerance test (OGTT).

Urinary levels of NAG vary with changes in plasma glucose levels in patients with type 1 or type 2 DM [11](#jcla21549-bib-0011){ref-type="ref"}, [16](#jcla21549-bib-0016){ref-type="ref"}. In addition, our recent longitudinal study has shown that urinary levels of NAG are significantly related to long‐term blood glucose control in elderly patients with type 2 DM [17](#jcla21549-bib-0017){ref-type="ref"}.

The first major aim of the present study was to examine how plasma glucose, urine glucose, and insulin levels during the OGTT are related to urinary NAG levels in subjects in the prediabetic state. The second aim was to examine when during the OGTT the plasma glucose most closely relates to urinary NAG levels in subjects with prediabetes. In addition, the final aim of this study was to examine the relationships between glycemic status and other markers of renal function.

MATERIALS AND METHODS {#jcla21549-sec-0060}
=====================

Diagnostic 75‐g OGTTs were administered at the Nippon Medical School Hospital from December 2005 through August 2010 to 80 patients (33 men and 47 women, aged 18--79 years) who had not yet received a diagnosis of DM and in whom HbA1c levels were ≤6.8% and fasting plasma glucose levels were \<7.0 mmol/l. On the basis of the OGTT and World Health Organization (WHO) criteria [18](#jcla21549-bib-0018){ref-type="ref"}, patients were placed into a normal glucose tolerance (NGT) group, an IGT group, or a DM group.

Subjects were excluded on the basis of the following criteria: pregnancy, previous gastrectomy, anemia, severe illness, serum creatinine (Cr) level ≥ 97.24 μmol/l (1.10 mg/dl), urine protein test \> 1+ (equivalent to \> 0.3 g/l), renal glucosuria, liver cirrhosis, chronic hepatitis, history of coronary artery disease (defined as symptoms of ischemia with simultaneous ischemic changes on electrocardiography or a history of myocardial infarction), urolithiasis, and chronic urinary tract infection.

The OGTTs were performed after an overnight fast of 12--14 hr. Subjects ingested a simple carbohydrate solution equivalent to 75 g of glucose (Torelan‐G, Shimizu Pharmaceuticals, Shimizu, Japan), and blood samples were obtained after 0, 30, 60, and 120 min. Plasma glucose levels were determined from specimens of venous blood by means of the glucose oxidase method. Plasma immunoreactive insulin (IRI) levels were determined with solid‐phase radioimmunoassay. Levels of HbA1c (normal range, 4.1--5.9%) were assayed with high‐performance liquid chromatography (Auto A1C analyzer; Arkray, Inc., Kyoto, Japan) according to the method of the Japanese Diabetes Society (JDS), which is equivalent to the internationally used HbA1c (%) (HbA1c \[NGSP\]) defined by the National Glycohemoglobin Standardization Program (NGSP), expressed by adding 0.4% to the HbA1c (JDS) (%) [19](#jcla21549-bib-0019){ref-type="ref"}.

Urinary glucose levels and serum Cr levels were measured with enzymatic assays. The serum levels of cystatin C were measured with the N Latex Cystatin C kit (Siemens Healthcare Diagnostics, Inc., Marburg, Germany) and the fully automated particle‐enhanced nephelometric immunoassay. Urinary NAG levels were measured spectrophotometrically with sodio‐meta‐cresolsulfonphthaleinyl‐*N*‐acetyl‐β‐D‐glucosaminide as a substrate (NAG assay kit, Shionogi & Co., Ltd., Osaka, Japan) [20](#jcla21549-bib-0020){ref-type="ref"}. This assay is specific for NAG, has no detectable reaction with other glycosidases, and has excellent sensitivity, with a linear range up to 200 U/l and excellent precision (coefficient of variation \<5%). The ratio of the urinary activity of NAG to Cr (NAG index) was determined in spot urine samples.

The estimated glomerular filtration rate (eGFR) was determined from serum Cr values and patient age using the new Japanese equation as follows [21](#jcla21549-bib-0021){ref-type="ref"}: $$\begin{array}{l}
{\text{eGFR}\text{(ml/min/1.73}\, m^{2}{) = 194 \times \text{age}}\text{(years)}^{- 0.28}} \\
{\quad \times \,\text{serum}\text{Cr}\text{(mg/dl)}^{- 1.094} \times 0.739\,\text{(if}\text{the}\text{subject}\text{was}} \\
{\quad\text{a}\text{woman).}} \\
\end{array}$$

Serum and urinary concentrations of β2‐microglobulin (β2MG) were measured with a latex immunoassay kit (Wako Pure Chemical Industries, Ltd., Osaka, Japan). The urinary albumin‐to‐Cr ratio (ACR) was measured with radioimmunoassay. Specimens of blood and urine were obtained while the subjects were fasting. The urinary NAG index, levels of β2MG, and the ACR were determined in spot samples of second morning urine specimens. Blood pressure was measured with the subject in a sitting position. The body‐mass index (BMI) was calculated. Insulin resistance was measured with the homeostasis model assessment of insulin resistance (HOMA‐R) using fasting IRI and the fasting plasma glucose level during the OGTT [22](#jcla21549-bib-0022){ref-type="ref"} as follows: $$\begin{array}{l}
{\text{HOMA‐R}\text{=}\text{fasting}\text{IRI}\left( \mu U/{ml} \right) \times \text{fasting}\text{plasma}} \\
{\quad\text{glucose}\text{(mmol/l)/22.5}} \\
\end{array}$$

Measurements were made using the area under the curve of glucose (AUC \[glu\]) andinsulin during the OGTT.

The Mann--Whitney *U*‐test, the Kruskal--Wallis *H*‐test, Pearson\'s correlation, and multiple linear regression analysis were used for statistical analysis of the data. A value of *P* \< 0.05 was considered to indicate statistical significance. All statistical tests were performed with a statistical software program (IBM SPSS statistics, version 12, IBM Corp., Armonk, NY). All data are presented as means ± SD.

Subjects were divided into three groups according to their glycemic response to the OGTT. No subjects showed impaired glucose tolerance (IGT) with fasting alone (fasting glucose ≥6.1 and \< 7.0 mmol/l and 120‐min glucose \<7.8 mmol/l). The three groups were defined according to WHO criteria [18](#jcla21549-bib-0018){ref-type="ref"} as follows: the NGT group: fasting glucose \<6.1 mmol/l and 120‐min glucose \<7.8 mmol/l; the IGT group: fasting glucose \<7 mmol/l and 120‐min glucose ≥7.8 and \<11.1 mmol/l; and the DM group: fasting glucose ≥7 mmol/l or 120‐min glucose ≥11.1 mmol/l or both.

All examinations were performed in the outpatient clinic of our hospital. Before the start of the study, informed consent was obtained from all subjects.

RESULTS {#jcla21549-sec-0070}
=======

On the basis of the OGTT and WHO criteria, NGT was diagnosed in 42 subjects, IGT in 31, and DM in 7. The clinical characteristics of the subjects are shown in Table [1](#jcla21549-tbl-0001){ref-type="table"}, and glucose levels at each time point during the OGTT are shown in Figure [1](#jcla21549-fig-0001){ref-type="fig"}. The BMI was higher in the DM group than in the NGT group or the IGT group, but the difference was not statistically significant.

###### 

Clinical Characteristics of Study Subjects

  Clinical characteristics OGTT status   NGT            IGT            DM             All            *P*‐value
  -------------------------------------- -------------- -------------- -------------- -------------- ---------------------------------------------------------
  *N*                                    42             31             7              80             --
  Age (years)                            61.1 ± 17.2    66.3 ± 9.4     57.7 ± 15.1    62.8 ± 14.6    0.441
  Men/women                              15/27          13/18          5/2            33/47          0.209
  BMI (kg/m^2^)                          23.4 ± 3.9     24.6 ± 3.2     27.1 ± 4.4     24.2 ± 3.7     0.050
  Systolic blood pressure (mmHg)         123.8 ± 14.1   129.7 ± 16.1   133.1 ± 10.7   126.9 ± 14.9   0.129
  Diastolic blood pressure (mmHg)        73.8 ± 9.6     75.9 ± 11.5    82.6 ± 4.9     75.4 ± 10.3    0.092
  Hypertension (%)                       47.6           77.4           71.4           61.3           0.031[\*](#jcla21549-tbl1-note-0003){ref-type="fn"}
  Antihypertensive medication (%)        38.1           51.6           71.4           46.3           0.199
  ACE inhibitors/ARBs (%)                23.8           41.9           42.9           32.5           0.327
  Total cholesterol (mmol/l)             5.05 ± 0.72    5.30 ± 1.21    4.99 ± 0.72    5.14 ± 0.94    0.784
  LDL cholesterol (mmol/l)               2.86 ± 0.58    3.05 ± 0.91    2.99 ± 0.56    2.94 ± 0.72    0.733
  Triglycerides (mmol/l)                 1.20 ± 0.62    1.92 ± 3.06    1.54 ± 0.72    1.51 ± 1.99    0.294
  Serum albumin (g/l)                    44.0 ± 3.0     44.0 ± 2.0     45.0 ± 3.0     44.0 ± 3.0     0.930
  Uric acid (μmol/l)                     309.3 ± 89.2   303.3 ± 65.4   333.1 ± 35.7   309.3 ± 77.3   0.476
  FPG (mmol/l)                           5.03 ± 0.42    5.63 ± 0.60    6.35 ± 0.85    5.38 ± 0.67    \<0.001[\*\*](#jcla21549-tbl1-note-0003){ref-type="fn"}
  HbA1c (%)                              5.78 ± 0.33    6.16 ± 0.36    6.61 ± 0.47    6.00 ± 0.47    \<0.001[\*\*](#jcla21549-tbl1-note-0003){ref-type="fn"}
  Serum Cr (μmol/l)                      60.2 ± 10.6    59.3 ± 14.2    59.3 ± 10.6    59.3 ± 11.5    0.730
  Urinary pH                             6.19 ± 0.89    5.97 ± 0.71    6.00 ± 0.58    6.09 ± 0.80    0.491

Data are expressed as mean ± SD.

BMI, body mass index; LDL cholesterol, low‐density lipoprotein cholesterol; ACE inhibitors, angiotensin‐converting enzyme inhibitors; ARBs, angiotensin receptor blockers; FPG, fasting plasma glucose.

\**P* \< 0.05; \*\**P* \< 0.005.

John Wiley & Sons, Ltd.

![Changes in plasma glucose (a), urine glucose (b), and IRI (c) concentrations during a 75‐g oral glucose tolerance test (OGTT). IRI, immunoreactive insulin; NGT, normal glucose tolerance; IGT, impaired glucose tolerance; DM, diabetes mellitus.\
^†^ *P* \< 0.005, \**P* \< 0.05.](JCLA-26-473-g001){#jcla21549-fig-0001}

The HbA1c level was positively associated with glycemic status (the Kruskal--Wallis *H*‐test), and the HbA1c level was significantly higher in the DM group (*P* \< 0.05, Mann--Whitney *U*‐test). The three groups did not differ significantly in regard to age, sex, systolic or diastolic blood pressure, total cholesterol, low‐density lipoprotein cholesterol, triglycerides, serum albumin, uric acid, serum Cr, or urinary pH. The prevalence of hypertension was positively associated with glycemic status and the development of glucose intolerance.

The plasma and urine levels of glucose and IRI during the OGTT are shown in Figure [1](#jcla21549-fig-0001){ref-type="fig"}. Mean plasma and urine glucose levels differed significantly between the NGT, IGT, and DM groups at each time point of the OGTT (Fig. [1](#jcla21549-fig-0001){ref-type="fig"}a, b). Mean plasma IRI levels differed significantly between the NGT, IGT, and DM groups at 0 and 120 min of the OGTT (Fig. [1](#jcla21549-fig-0001){ref-type="fig"}c).

Figure [2](#jcla21549-fig-0002){ref-type="fig"} shows the associations between markers of renal function and glycemic status (assessed with OGTT: NGT, IGT, and DM). The three groups did not differ significantly with regard to levels of cystatin C, eGFR, serum β2MG, urinary β2MG, or urinary ACR. Only urinary NAG showed a significant difference (*P* = 0.016): the urinary NAG level in the DM group (8.53 ± 4.96 U/ g UCr) was significantly higher than that in the NGT group (5.40 ± 3.82 U/g UCr; *P* = 0.020), and that in the IGT group (6.60 ± 2.88 U/g UCr) was significantly higher than that in the NGT group (5.40 ± 3.82 U/g UCr; *P* = 0.027). The urinary NAG level in the DM group was slightly but not significantly higher than that in the IGT group (*P* = 0.460). The urinary NAG level was positively correlated with patient age (*r* = 0.404, *P* \< 0.001) and with the plasma glucose level at 120 min of the OGTT (*r* = 0.320, *P* = 0.004). However, age was not positively correlated with the plasma glucose levels at 120 min (*r* = 0.162, *P* = 0.151).

![Renal markers in 80 subjects in the prediabetic state. Urinary NAG index (U/g UCr), eGFR (ml/min/1.73 m^2^), serum cystatin C (mg/l), serum β2MG (mg/l), urinary β2MG (μg/l), urinary ACR (mg/mmol) by glycemic status (assessed with a 75‐g oral glucose tolerance test \[OGTT\]). Urinary NAG index, urinary *N*‐acetyl‐β‐[d]{.smallcaps}‐glucosaminidase index; eGFR, estimated glomerular filtration rate; β2MG, β2‐microglobulin; ACR, albumin‐to‐Cr ratio; NGT, normal glucose tolerance; IGT, impaired glucose tolerance; DM, diabetes mellitus; ns, not significant. Data are expressed as mean ± SD.](JCLA-26-473-g002){#jcla21549-fig-0002}

Multiple linear regression analyses showed that the urinary NAG level was significantly and positively associated with the plasma glucose level at 120 min of the OGTT when corrected for age, sex, systolic blood pressure, serum levels of Cr and total cholesterol, and BMI (Table [2](#jcla21549-tbl-0002){ref-type="table"}). Furthermore, multiple linear regression analysis showed a similar relation between the urinary NAG level and glycemic status.

###### 

Multiple Linear Regression Analyses of Urinary NAG Index in Relation to Other Variables

                             Dependent variable:                                                                              Dependent variable:                                                                                     
  ---------------- --------- --------------------- -------- ------------------------------------------------------- --------- --------------------- --------- -------- -------- ----------------------------------------------------- ---------
  Plasma glucose    Model 1  0.095                 0.846    0.400                                                   0.009     IRI                   Model 1   0.001    0.006    0.995                                                 \<0.001
  0 min             Model 2  0.135                 1.141    0.258                                                   0.208     0 min                 Model 2   0.163    1.386    0.170                                                 0.214
  Plasma glucose    Model 1  0.063                 0.561    0.576                                                   0.004     IRI                   Model 1   −0.082   −0.730   0.468                                                 0.007
  30 min            Model 2  −0.037                −0.309   0.758                                                   0.195     30 min                Model 2   −0.067   −0.565   0.574                                                 0.197
  Plasma glucose    Model 1  0.081                 0.718    0.475                                                   0.006     IRI                   Model 1   −0.158   −1.421   0.159                                                 0.025
  60 min            Model 2  0.034                 0.284    0.777                                                   0.194     60 min                Model 2   −0.154   −1.268   0.209                                                 0.210
  Plasma glucose    Model 1  0.320                 3.003    0.004[\*\*](#jcla21549-tbl2-note-0004){ref-type="fn"}   0.102     IRI                   Model 1   0.080    0.717    0.476                                                 0.006
  120 min           Model 2  0.319                 2.975    0.004[\*\*](#jcla21549-tbl2-note-0004){ref-type="fn"}   0.282     120 min               Model 2   0.113    0.979    0.331                                                 0.204
  Urine glucose     Model 1  0.013                 0.112    0.911                                                   \<0.001   AUC (glu)             Model 1   0.154    1.383    0.170                                                 0.024
  0 min             Model 2  0.138                 1.230    0.223                                                   0.209                           Model 2   0.116    0.982    0.329                                                 0.204
  Urine glucose     Model 1  0.079                 0.705    0.483                                                   0.006     HbA1c                 Model 1   0.161    1.451    0.151                                                 0.026
  30 min            Model 2  0.128                 1.182    0.241                                                   0.208                           Model 2   0.184    1.661    0.101                                                 0.223
  Urine glucose     Model 1  −0.033                −0.295   0.768                                                   0.001     OGTT status           Model 1   0.253    2.320    0.023[\*](#jcla21549-tbl2-note-0004){ref-type="fn"}   0.064
  60 min            Model 2  −0.009                −0.072   0.943                                                   0.193     NGT/IGT/DM            Model 2   0.297    2.723    0.008[\*](#jcla21549-tbl2-note-0004){ref-type="fn"}   0.269
  Urine glucose     Model 1  0.046                 0.412    0.682                                                   0.002     HOMA‐R                Model 1   0.050    0.443    0.659                                                 0.002
  120 min           Model 2  0.104                 0.890    0.376                                                   0.202                           Model 2   0.208    1.806    0.075                                                 0.228

Urinary NAG index, urinary *N*‐acetyl‐β‐[d]{.smallcaps}‐glucosaminidase index; IRI, immunoreactive insulin; AUC (glu), the area under the curve of glucose; HOMA‐R, homeostasis model assessment of insulin resistance; NGT, normal glucose tolerance; IGT, impaired glucose tolerance; DM, diabetes mellitus; BMI, body mass index; ACR, urinary albumin‐to‐Cr ratio.

Number of dummy variables: 1, OGTT‐NGT; 2, IGT; 3, DM.

Model 1: uncorrected; Model 2: corrected as for age, sex, systolic blood pressure, serum Cr, total cholesterol, BMI, and ACR.

\**P* \< 0.05; \*\**P* \< 0.005.

John Wiley & Sons, Ltd.

No statistically significant associations were observed between the urinary NAG and plasma glucose levels at preloading, 30 min or 60 min of the OGTT, urine glucose levels at preloading or during the OGTT, AUC (glucose), HbA1c, or HOMA‐R. Furthermore, there were no statistically significant differences between the insulin levels at preloading or during the OGTT, the homeostasis model assessment of β‐cell function (HOMA‐β), or the insulinogenic index.

DISCUSSION {#jcla21549-sec-0080}
==========

The main finding of the present study is that urinary NAG levels are significantly and positively correlated with plasma glucose levels at 120 min of the OGTT in the prediabetic state. Increased urinary levels of NAG indicate proximal tubular damage, because the highest concentrations of NAG are located in the renal proximal tubules [6](#jcla21549-bib-0006){ref-type="ref"}. To date, few studies have examined the association of tubular markers with the severity of renal function in diabetic nephropathy. Previous studies have shown that the urinary level of NAG and the levels of other markers of tubular damage are correlated with urinary albumin excretion [23](#jcla21549-bib-0023){ref-type="ref"}, [24](#jcla21549-bib-0024){ref-type="ref"}. Several studies have found that even in patients with normoalbuminuric DM, urinary NAG levels are already higher than in subjects without diabetes [24](#jcla21549-bib-0024){ref-type="ref"}, [25](#jcla21549-bib-0025){ref-type="ref"}. On the basis of these data, Nauta et al. [25](#jcla21549-bib-0025){ref-type="ref"} have proposed that the tubulointerstitium plays a role in the pathogenesis and progression of nephropathy in patients with DM.

Urinary NAG levels generally rise and fall according to the degree of glycemic control in patients with diabetes [26](#jcla21549-bib-0026){ref-type="ref"}. Increased urinary NAG levels have been reported in both type 1 and 2 DM [11](#jcla21549-bib-0011){ref-type="ref"}, [12](#jcla21549-bib-0012){ref-type="ref"}. Furthermore, Fujita et al. [14](#jcla21549-bib-0014){ref-type="ref"} have found that urinary NAG excretion is slightly but significantly higher in subjects with sustained IGT than in control subjects with NGT. Another study has shown that urinary NAG excretion is significantly increased in patients with IGT [15](#jcla21549-bib-0015){ref-type="ref"}. The present study also found that the urinary excretion of NAG was correlated with glycemic status (assessed with an OGTT). These findings of some previous studies are consistent with our present findings, because the most difference between NGT and IGT is the postload glucose levels of the OGTT. In addition, Hiratsuka et al. has shown no significant associations between urinary albumin, urinary β~2~‐microglobulin, and glycemic status (i.e., NGT, IGT, or DM) [15](#jcla21549-bib-0015){ref-type="ref"}. The present study obtained similar findings.

Urinary NAG levels increase with age [27](#jcla21549-bib-0027){ref-type="ref"}, [28](#jcla21549-bib-0028){ref-type="ref"}, [29](#jcla21549-bib-0029){ref-type="ref"}. To examine the relationship between urinary NAG levels and age, we have determined the NAG index in 137 healthy subjects, aged 19--88 years [28](#jcla21549-bib-0028){ref-type="ref"}. This cross‐sectional study found that urinary NAG levels increase with age at a rate of 0.65 U/g UCr per decade. In the present study, nearly two‐thirds of the subjects (65%) were older than 60 years. Multiple linear regression analysis of all models in the present study identified only age as an independent predictor of increased urinary NAG. Therefore, this result confirms the relationship between urinary NAG levels and age. Hyperglycemia, IGT, and type 2 DM become progressively more common with advancing age [30](#jcla21549-bib-0030){ref-type="ref"}, [31](#jcla21549-bib-0031){ref-type="ref"}, [32](#jcla21549-bib-0032){ref-type="ref"}, [33](#jcla21549-bib-0033){ref-type="ref"}. The increase in plasma glucose levels at 120 min of the OGTT is significantly greater in elderly subjects than in younger subjects [33](#jcla21549-bib-0033){ref-type="ref"}. Furthermore, another study has suggested that the age‐related decline in glucose metabolism has only a small effect on the fasting plasma glucose concentration, which increases by 1 mg/dl per decade. In contrast, following oral glucose ingestion, the 60‐min plasma glucose response has been shown to increase by 0.22--0.78 mmol/l (4--14 mg/dl) (mean = 0.5 mmol/l \[mean = 9 mg/dl\]) per decade and the 120‐min plasma glucose value by 0.06--0.61 mmol/l (1--11 mg/dl) (mean = 0.28 mmol/l \[mean = 5 mg/dl\]) per decade [34](#jcla21549-bib-0034){ref-type="ref"}.

In the present study, the urinary excretion of NAG was correlated with the plasma glucose level at 120 min of the OGTT when the data were corrected for age, sex, systolic blood pressure, serum levels of Cr and total cholesterol, BMI, and urinary ACR. Neither the plasma glucose level at preloading of the OGTT nor the HbA1c level was correlated with the urinary excretion of NAG. To investigate the correlation between the glucose levels after load and urinary NAG in younger patients, we excluded elderly subjects and performed multivariate analysis in 29 subjects (60 years or younger). The glucose value at 120 min (*P* = 0.003) was the most significantly related with urinary NAG index and was followed by the 60 min glucose value (*P* = 0.030), but the 30 min glucose value was not significantly related (data not shown). In our analysis, the most significant correlation was seen in the 120 min glucose value in younger patients as well. However, the 60 min glucose value also had significant correlation. Unfortunately, the plasma glucose level at 90 min of the OGTT was not measured in the present study, but the 90 min glucose value may have had the strongest correlation in younger patients. We would like to study a larger number of younger patients and measure 90 min glucose values in the future.

Recently, many studies have found that the serum 1,5‐AG level generally reflects postprandial hyperglycemia [35](#jcla21549-bib-0035){ref-type="ref"} but not fasting hyperglycemia [36](#jcla21549-bib-0036){ref-type="ref"}. A strong negative correlation has also been found between the serum 1,5‐AG level and the plasma glucose level at 120 min of the OGTT in subjects with IGT [35](#jcla21549-bib-0035){ref-type="ref"}. A study by Yamanouchi et al. has found that the serum 1,5‐AG level and the urinary NAG level are related [13](#jcla21549-bib-0013){ref-type="ref"}; this study also found that urinary excretion of NAG is associated with a change in the serum 1,5‐AG level and is quickly reversible when the serum 1,5‐AG level improves in type 2 DM. In the 3 years after the onset of diabetes, Yamanouchi et al. [13](#jcla21549-bib-0013){ref-type="ref"} obtained at least 18 measurements of one variable for each patient (*n* = 112) and calculated the means. The urinary NAG level was found to be significantly correlated with the fasting plasma level of glucose (*r* = 0.512, *P* \< 0.0001), the level of HbA1 (*r* = 0.351, *P* = 0.001) and, especially, with the level of 1,5‐AG (*r* = −0.790, *P* \< 0.0001). These findings are consistent with our present findings that the urinary NAG level was correlated with the plasma glucose level at 120 min of the OGTT, and the possibility tubular damage is induced by postprandial hyperglycemia. Between 99% and 100% of 1,5‐AG is reabsorbed in normoglycemia, but the reabsorption rate decreases significantly in hyperglycemia in approximate proportion to the degree of the hyperglycemia above the renal threshold for glucosuria [37](#jcla21549-bib-0037){ref-type="ref"}.

Moreover, although there are individual differences in the renal threshold for glucosuria, when the plasma glucose level is higher, the urinary excretion of glucose increases. In general, the renal threshold for glucosuria is a plasma glucose level of 9--10 mmol/l (160--180 mg/dl) or more. Therefore, in patients in a prediabetic state, glucosuria appears during the OGTT but not at preloading of the OGTT. When the previous study of the relationship between urinary NAG levels and the serum 1,5‐AG levels is taken into account, it is necessary to examine both the relationship between urinary NAG levels and urine glucose levels and the relationship between urinary NAG levels and plasma glucose levels during the OGTT. To our knowledge, no previous reports have examined the relationship between urinary NAG levels and plasma or urine glucose levels during the OGTT. In the present study, we investigated the relationship between urinary NAG levels and plasma or urine glucose levels during the OGTT and found no statistically significant association between urinary NAG levels and urine glucose levels at preloading or during the OGTT.

Several studies have found that urinary NAG levels are not consistently correlated with the severity of hypertension [4](#jcla21549-bib-0004){ref-type="ref"}, [27](#jcla21549-bib-0027){ref-type="ref"}, [38](#jcla21549-bib-0038){ref-type="ref"}. Schnoell et al. [39](#jcla21549-bib-0039){ref-type="ref"} have reported that urinary NAG did not differ significantly between hypertensive and normotensive patients with diabetes. In addition, our previous study showed no evidence that urinary NAG levels are related to blood pressure [28](#jcla21549-bib-0028){ref-type="ref"}. Furthermore, Sano et al. [40](#jcla21549-bib-0040){ref-type="ref"} found that in patients with type 2 DM and persistent microalbuminuria, although the angiotensin‐converting enzyme (ACE) inhibitor enalapril reduced urinary albumin excretion in both normotensive patients and patients with well‐controlled hypertension, urinary NAG levels were not decreased in either group. However, combined administration of the ACE inhibitor perindopril and the diuretic indapamide reduces urinary NAG excretion in type 2 DM [26](#jcla21549-bib-0026){ref-type="ref"}. In the present study, we found that neither systolic nor diastolic blood pressure differed among subjects with NGT, IGT, or DM. There was no difference in the percentages of patients being treated with ACE inhibitors or angiotensin receptor blockers (ARBs) among the NGT, IGT, and DM groups. There was no simple correlation between urinary NAG and systolic blood pressure or between urinary NAG and diastolic blood pressure in any subject. Multiple linear regression analysis found no correlation between systolic blood pressure and urinary NAG levels when the data were corrected for demographic factors. This finding is in concordance with those of most previous studies. The results of linear regression analysis remained valid when the data were corrected for a history of ACE inhibitor or ARB use but not for systolic blood pressure. A similar result was obtained when the data were corrected for both the systolic blood pressure and history of ACE inhibitor or ARB use.

In the present study, the ratio of the urinary activity of NAG to Cr (NAG index) was determined in spot urine specimens. The NAG index in random urine specimens provides a useful and convenient means of assessing daily NAG excretion and avoids many of the problems of 24‐hr collection. A study by Ellis et al. [11](#jcla21549-bib-0011){ref-type="ref"} has found that the correlation coefficient for the NAG index in random early morning urine specimens versus 24‐hr NAG excretion in children with diabetes was 0.80.

Urinary levels of NAG are increased in various renal diseases, including glomerulonephritis, tubulointerstitial diseases, renal allograft rejection, and toxic renal injury [7](#jcla21549-bib-0007){ref-type="ref"}, [8](#jcla21549-bib-0008){ref-type="ref"}, [9](#jcla21549-bib-0009){ref-type="ref"}, [10](#jcla21549-bib-0010){ref-type="ref"}. These observations suggest that the glucose levels at 120 min of the OGTT must be taken into account in subjects without diabetes when the urinary NAG index is examined. Although a positive correlation between glucose tolerance and NAG activity has been reported [14](#jcla21549-bib-0014){ref-type="ref"}, before the present study little was known about the relationship between urinary NAG levels and glucose or insulin levels at each time point of the OGTT.

The present study had several limitations. First, this study was a single‐center study and might have involved self‐selection bias. Second, because our study used a cross‐sectional design, cause--effect relationships cannot be inferred. The urinary NAG level was measured at only one time point, and the OGTT was performed only once. Third, the mechanism by which hyperglycemia increases urinary NAG excretion remains unclear. When we reviewed earlier studies and considered the limitations mentioned above, we concluded that glucose intolerance was probably not caused by the increased urinary levels of NAG. When a possible correlation between postprandial glucose levels and the OGTT is considered, postprandial hyperglycemia may cause tubular damage. This study suggests that the urinary excretion of NAG with other urinary enzymes in the prediabetic state is an appropriate biomarker for screening for prediabetic renal dysfunction. The present data suggest that the increasing urinary levels of NAG are related to both the structural damage and the functional damage caused by hyperglycemia. Longitudinal studies are needed to fully clarify the underlying causes. When the postprandial glucose levels decrease, urinary NAG levels may decrease as well. Therefore, markers other than postprandial glucose related to the decrease in urinary NAG levels should be investigated.

To our knowledge, this cross‐sectional study is the first to show, by means of multivariate analysis, a relationship between urinary NAG levels and plasma glucose, urine glucose, and IRI levels at each time point of the OGTT. In conclusion, these results suggest that postprandial hyperglycemia is an independent factor that causes renal tubular damage in prediabetic patients.
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